Nuestros expertos

Flavio Guzmán, M.D.

Flavio Guzmán, M.D.

Editor & CEO
Psychopharmacology Institute

Biografía

No se ha encontrado ninguna biografía.

Publicaciones de Flavio Guzmán, M.D.

Resumen del primer trimestre de 2026: milsaperidona, agonistas del receptor GLP-1 y zuranolona

0,50 CMEs
Why did the FDA approve milsaperidone if it offers no clinical advantage over iloperidone? What does the FDA's removal of the GLP-1 suicidality warning mean for your practice? How does ACOG's updated guidance position zuranolone for severe postpartum depression?
Flavio Guzmán, M.D.
Psychopharmacology Institute
Ver más información

Guía de venlafaxina: farmacología, indicaciones, pautas de dosificación y efectos adversos

0,50 CMEs
This guide covers pharmacodynamics, pharmacokinetics, dosage forms, indications, side effects, and use in special populations. It also discusses venlafaxine's mechanism of action, metabolism, and FDA-approved and off-label uses.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Ver más información

Citalopram y escitalopram: resumen de las principales diferencias y similitudes

0,50 CMEs
This article provides an in-depth comparison of citalopram and escitalopram, covering their chemical composition, pharmacokinetics, FDA-approved indications, off-label uses, potential side effects, and the risk of QT prolongation associated with both drugs. Furthermore, it addresses crucial considerations for prescribing these medications to specific patient populations.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Ver más información

Guía práctica de fluoxetina: farmacología, indicaciones, pautas de dosificación y efectos adversos

0,50 CMEs
Fluoxetine is a potent serotonin reuptake inhibitor with a long half-life. It is FDA-approved for depression, OCD, panic disorder and bulimia. Fluoxetine also has off-label uses like treating repetitive behaviors in autism. This guide covers fluoxetine's pharmacology, dosing, side effects and use in special populations.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Ver más información

Guía práctica de fluvoxamina: farmacología, indicaciones, pautas de dosificación y efectos adversos

0,50 CMEs
Fluvoxamine (Luvox) is approved for OCD in both pediatric and adult patients in the U.S. There is no definitive evidence suggesting it is more effective than other SSRIs for OCD. It is also approved for depression in the UK. Fluvoxamine is an inhibitor of CYP1A2 and should not be combined with MAOIs.
Flavio Guzmán, M.D.
Psychopharmacology Institute
Ver más información

Explore nuestra biblioteca de más de 440 Video Lectures, podcasts, resúmenes de investigación y entrevistas con expertos.

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.